CONF-ADA — ADA Standards of Care 2025, Section 8: Obesity and Weight Management

[DRAFT — authored 2026-04-18. Guideline reference.]

Source

American Diabetes Association. Standards of Care in Diabetes — 2025. Section 8: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care. 2025;48(Suppl. 1):S167-S184.

External URL: ADA Standards of Care 2025 Section 8

Scope

Annually updated guideline from the ADA Professional Practice Committee synthesizing evidence on obesity pharmacotherapy, nutrition, behavioral therapy, and metabolic/bariatric surgery for prevention and treatment of T2D.

Key Recommendations (Pharmacotherapy Focus)

Preferred GLP-1 and Dual Agonist Agents

1. Semaglutide (Wegovy 2.4 mg weekly SC): Recommended for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity. Benefit amplified in T2D + ASCVD (SELECT evidence).

2. Tirzepatide (Zepbound 5-15 mg weekly SC): Recommended on same BMI criteria. Preferred in patients prioritizing maximum weight reduction based on SURMOUNT-1 evidence.

3. Oral semaglutide 14 mg: Alternative in T2D patients unable or unwilling to use injectable; CV benefit (SOUL, published after guideline text-lock) may prompt 2026 update.

Framework for Agent Selection

• ASCVD/CKD: Prefer semaglutide (SELECT, FLOW) or tirzepatide (SURMOUNT-CVOT ongoing — tirzepatide recommendation positioned pending outcome).
• Heart failure HFpEF: Semaglutide (STEP-HFpEF) or tirzepatide (SUMMIT).
• Sleep apnea: Tirzepatide (SURMOUNT-OSA).
• MASH/MASLD: Tirzepatide (Sanyal 2024 NEJM) or semaglutide (Newsome 2021) — dedicated Section 4 liver disease guidance.

Duration & Discontinuation

• Weight regain expected on cessation (STEP 1 Extension, SURMOUNT-4).
• Maintenance of benefits requires indefinite treatment; counseling on this point is essential pre-initiation.
• Weight-maintenance dose titration not yet evidence-based — continue trial-validated dose.

Compounded Products

• The ADA does NOT endorse compounded semaglutide or tirzepatide.
• Guideline references FDA shortage-ending notices and FAERS dosing-error reports.
• Practitioners should use only FDA-approved branded products for guideline-concordant care.

Additional Module 5-Relevant Content

• Metabolic/bariatric surgery: Remains gold standard for BMI ≥40 or ≥35 with comorbidity; superior durability over GLP-1 monotherapy.
• Behavioral and lifestyle intervention: Remains foundation — drug therapy adjunct, not replacement.
• Pediatric T2D and obesity: Section 14 (separate) covers STEP TEENS and SURPASS-PEDS data — GLP-1/GIP-GLP-1 pharmacotherapy endorsed as of 2025 edition for adolescents ≥12 years.

Limitations

• Section 8 text-lock occurred September 2024; SOUL (2025), STRIDE (2025), Wegovy HD approval (March 2026), EMA NAION classification (June 2025) post-date text lock.
• 2026 Standards of Care should integrate these.

Linked Peptides

• Semaglutide
• Tirzepatide
• Retatrutide (pipeline — not yet endorsed)

Related References

• CONF-ADA-StandardsOfCare-2026 – ADA Obesity and Weight Management T2DM
• PMID-37952131 – SELECT Semaglutide Cardiovascular Outcomes in Obesity
• PMID-35658024 – SURMOUNT-1 Tirzepatide for Obesity
• PMID-38785209 – FLOW Semaglutide Kidney Outcomes CKD T2DM

Orchestrator Notes

• Primary guideline anchor for Lesson 5.1 evidence-based framework.
• Patient selection rubric in Lesson 5.2 aligns with these recommendations.
• Confirm Section 8 (not Section 9 or 14) when citing.

Tags

#guideline #ada #standards-of-care #obesity #t2dm #pharmacotherapy #glp1 #2025